Eisai Corporation of North America Announces Appointment of Vice President of U.S....

Eisai Corporation of North America Announces Appointment of Vice President of
U.S. Corporate Communications

WOODCLIFF LAKE, N.J., April 17 /PRNewswire/ -- Eisai Corporation of North
America today announces the immediate appointment of Robert Laverty as Vice
President of U.S. Corporate Communications. In this newly created position,
Mr. Laverty will be responsible for overseeing and coordinating all of Eisai's
corporate communications strategies and activities in the United States.
Mr. Laverty brings to Eisai more than 22 years of global corporate,
product, policy and research and development communications experience in the
pharmaceutical industry. Most recently, he served as Vice President, Global
Communications, Malaria Initiatives for Novartis AG, where he oversaw all
global communications supporting the company's malaria initiative in the
developing world. In addition, Mr. Laverty has held several other executive
titles at Novartis Pharmaceuticals Corp, including Vice President, External
Communication and Vice President, Global Pharma Media Relations.
Earlier in his career, Mr. Laverty held a number of progressively
responsible positions in corporate policy, corporate affairs, and product
public affairs at Bristol-Myers Squibb Company. He holds a Bachelor of
Science degree in pharmacy from St. John's University, Jamaica, New York.
"Mr. Laverty is a welcome addition to our company and will be instrumental
in strengthening Eisai's visibility and presence in the U.S. as a top-20
pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporation
of North America. "With his more than two decades of senior communications
expertise in the global pharmaceutical industry, Mr. Laverty's contributions
to our company will be invaluable, as we continue to fulfill our human health
care (hhc) mission to satisfy unmet medical needs and increase benefits to
patients and their families."
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai
Co., Ltd. and supports the activities of its operating companies in North
America. These operating companies include: Eisai Research Institute of
Boston, Inc., a discovery operation with strong organic chemistry
capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the
development of therapeutic monoclonal antibodies; Eisai Medical Research Inc.,
a clinical development group; Eisai Inc., a commercial operation with
manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and
commercial operation with manufacturing and marketing/sales functions; and
Eisai Machinery U.S.A., which markets and maintains pharmaceutical
manufacturing machinery. For more information about Eisai, please visit
www.eisai.com.
SOURCE Eisai Corporation of North America

Meg Alexander, Chandler Chicco Agency, +1-212-229-8437; Suzanne Grogan,
Manager, Corporate Planning and Communications of Eisai Inc., +1-201-746-2083